Last reviewed · How we verify

NCT04279496: CONFIRM2

Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry

ENROLLING BY INVITATION Last updated 26 November 2024
What this trial tests

trial in Coronary Artery Disease in 35,000 participants. Enrolling by invitation.

Timeline
1 June 2020
Primary endpoint
1 June 2027
1 June 2027

Quick facts

Lead sponsorCleerly, Inc.
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment35,000
Start date1 June 2020
Primary completion1 June 2027
Estimated completion1 June 2027
Sites1 location across United States

Conditions studied

Sponsor

Cleerly, Inc. — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of CONFIRM2 is to perform the largest cardiovascular phenotype outcomes study ever.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Relationship of age, atherosclerosis and angiographic stenosis using artificial intelligence.
    Jonas R, Earls J, Marques H, Chang HJ, et al · · 2021 · cited 15× · PMID 34785589 · DOI 10.1136/openhrt-2021-001832
  2. AI-Quantitative CT Coronary Plaque Features Associate With a Higher Relative Risk in Women: CONFIRM2 Registry.
    Feuchtner GM, Lacaita PG, Bax JJ, Rodriguez F, et al · · 2025 · cited 14× · PMID 40162910 · DOI 10.1161/circimaging.125.018235

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Cleerly, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04279496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing